GEO series

Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties

GSE270229 Homo sapiens; Mus musculus Expression profiling by high throughput sequencing 18 samples Submitted 2024/09/03 Platform GPL24247Platform GPL24676

Summary

Despite advances in breast cancer screening and treatment, prognosis for metastatic disease remains dismal at 30% five-year survival. This is due, in large, to the failure of current therapeutics to target properties unique to metastatic cells. One of the drivers of metastasis is miR-10b, a small noncoding RNA implicated in cancer cell invasion, migration, viability, and proliferation. We have developed a nanodrug termed MN-anti-miR10b that delivers anti-miR10b antisense oligomers to cancer cells. In mouse models of metastatic triple-negative breast cancer, MN-anti-miR10b has been shown to prevent onset of metastasis and eliminate existing metastasis in combination with chemotherapy even after treatment has been stopped. Recent studies have implicated miR-10b in conferring stem cell-like properties onto cancer cells, such as chemoresistance. In this study, we show transcriptional evidence that inhibition of miR-10b with MN-anti-miR10b activates developmental processes in cancer cells and that stem-like cancer cells have increased miR-10b expression. We then demonstrate that treatment of breast cancer cells with MN-anti-miR10b reduces their stemness confirming that these properties make metastatic cells susceptible to the nanodrug actions. Collectively, these findings indicate that inhibition of miR-10b functions to impair breast cancer cell stemness, positioning MN-anti-miR10b as an effective treatment option for stem-like breast cancer subtypes.

Published in

Halim A, Al-Qadi N, Kenyon E et al. · Oncotarget 2024 · PMID 39189967 · doi:10.18632/oncotarget.28641

This dataset

Open GSE270229 in finder → Find more RNA-seq datasets →

Download

Direct links to NCBI, no account and no request form: the whole study as GSE270229_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 18 samples. Raw sequencing reads are also available from ENA.

Whole study · RAW.tar ↓ Series matrix ↓ All supplementary files ↗ Raw reads on ENA ↗

Also filed as BioProject PRJNA1125448 and SRA study SRP514734. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 39189967) ↗

Study design

6 conditions, mostly in triplicate

231_MN ×3 231_MN_Anti10b ×3 231_NTC ×3 4T1_MN ×3 4T1_MN_Anti10b ×3 4T1_NTC ×3

Supports a between-group comparison across 18 samples.

6 replicated groups read from 18 sample titles; they account for 18 of them. Check it against the sample list below before relying on it.

Similar datasets

Search all RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.